Key result
Doubling baseline adiponectin is linked to ~2.6-fold higher odds of uncontrolled blood pressure.
Why the study?
Mean blood pressure changes can conceal individual gains and losses of control, motivating an examination of six-month office BP control transitions, treatment-class changes, and the association between baseline adiponectin and six-month non-control adjusted for kidney function.
Cohort (n=125)
Answers are grounded in this paper and cite their sources.
In a retrospective hypertension cohort, net improvements in six-month office blood pressure control masked individual transitions including loss of control in over a third of initially controlled patients, while baseline adiponectin failed to provide reliable prognostic value for non-control.
Background and Objectives: Mean blood pressure (BP) changes can conceal individual gains and losses of control. We described six-month office BP control transitions and recorded treatment-class changes, and explored the association between baseline adiponectin and six-month non-control with adjustment for kidney function. Materials and Methods: This retrospective secondary analysis included 125 adults with hypertension. Uncontrolled BP was defined as systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg. Paired analyses and control-state transitions used available follow-up data. Exploratory logistic models included age, baseline systolic BP, and sex, with additional adiponectin, estimated glomerular filtration rate (eGFR), and treatment sensitivity analyses. Multiplicity and selection-related optimism were examined. Results: Six-month BP was available for 91 participants. Control increased from 31/91 (34.1%) to 46/91 (50.5%; exact McNemar p = 0.020): 20 remained controlled, 26 achieved control, 11 lost control, and 34 remained uncontrolled. Mean paired systolic BP fell by 6.81 mmHg (95% confidence interval (CI) −11.47 to −2.16). Among 32 persistently uncontrolled participants with paired complete medication profiles, 4 had a net class-count increase. In 78 participants with adiponectin data, the adjusted odds ratio per doubling was 2.60 (95% CI 1.25–5.38); additional eGFR adjustment did not attenuate the estimate (2.70, 1.28–5.67). The univariable association did not survive false-discovery-rate correction (q = 0.094), and selection-inclusive internal validation did not establish stable incremental discrimination. Conclusions: Net improvement in office BP control coexisted with loss of control in 11/31 initially controlled attendees. Recorded class-count changes cannot establish therapeutic inertia or a programme effect. The adiponectin association remained exploratory after renal adjustment and does not support clinical testing or a prediction rule.
No takes yet. Share an insight, caveat, or question.
Craciun et al. (2026) conducted a cohort in Hypertension (n=125). Baseline adiponectin and routine hypertension management vs. Baseline blood pressure status / lower adiponectin was evaluated on Six-month office blood pressure control (SBP < 140 mmHg and DBP < 90 mmHg) and non-control (OR 2.60, 95% CI 1.25-5.38, p=0.020). Routine follow-up over 6 months increased office BP control from 34.1% to 50.5%, while doubling baseline adiponectin was associated with non-control.
Synapse has enriched 10 related papers. Consider them for comparative context: